Epigenetic regulation and cancer (review)

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 523-532

  Chen, Q W ^a,b   Zhu, X Y ^a,b   Li, Y Y ^c   Meng, Z Q ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cancer; DNA methylation; Epigenetics; Histone modification; MicroRNAs

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; MICRORNA; ROMIDEPSIN; VORINOSTAT;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; COLON CANCER; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

CARCINOGENESIS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84892430189     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2913     Document Type: Review

References (143)

1. Luger K, Mader AW, Richmond RK, Sargent DF and Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260, 1997.
2. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
3. Suzuki MM and Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476, 2008.
4. Rijnkels M, Kabotyanski E, Montazer-Torbati MB, Beauvais CH, Vassetzky Y, Rosen JM and Devinoy E: The epigenetic landscape of mammary gland development and functional differentiation. J Mammary Gland Biol Neoplasia 15: 85-100, 2010.
5. Bernstein BE, Meissner A and Lander ES: The mammalian epigenome. Cell 128: 669-681, 2007.
6. Watt F and Molloy PL: Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 2: 1136-1143, 1988.
7. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN and Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389, 1998.
8. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M and Schubeler D: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466, 2007.
9. Yamada Y, Shirakawa T, Taylor TD, et al: A comprehensive analysis of allelic methylation status of CpG islands on human chromosome 11q: comparison with chromosome 21q. DNA Seq 17: 300-306, 2006.
10. Kouzarides T: Chromatin modifications and their function. Cell 128: 693-705, 2007.
11. Cheung P, Allis CD and Sassone-Corsi P: Signaling to chromatin through histone modifications. Cell 103: 263-271, 2000.
12. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR and Price BD: Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 11: 1376-1382, 2009.
13. Li B, Carey M and Workman JL: The role of chromatin during transcription. Cell 128: 707-719, 2007.
14. Li Y, Sun L, Zhang Y, et al: The histone modifications governing TFF1 transcription mediated by estrogen receptor. J Biol Chem 286: 13925-13936, 2011.
15. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
16. Rouhi A, Mager DL, Humphries RK and Kuchenbauer F: MiRNAs, epigenetics, and cancer. Mamm Genome 19: 517-525, 2008.
17. Lim LP, Glasner ME, Yekta S, Burge CB and Bartel DP: Vertebrate microRNA genes. Science 299: 1540, 2003.
18. Lai EC, Tomancak P, Williams RW and Rubin GM: Computational identification of Drosophila microRNA genes. Genome Biol 4: R42, 2003.
19. Griffiths-Jones S: The microRNA Registry. Nucleic Acids Res 32: D109-D111, 2004.
20. Iorio MV, Piovan C and Croce CM: Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 1799: 694-701, 2010.
21. Friedman JM, Liang G, Liu CC, et al: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69: 2623-2629, 2009.
22. + T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184: 6773-6781, 2010.
23. Barber BA and Rastegar M: Epigenetic control of Hox genes during neurogenesis, development, and disease. Ann Anat 192: 261-274, 2010.
24. Martin GS: The road to Src. Oncogene 23: 7910-7917, 2004.
25. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
26. Dietrich D, Lesche R, Tetzner R, et al: Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem 57: 477-489, 2009.
27. Yballe CM, Vu TH and Hoffman AR: Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 81: 1607-1612, 1996.
28. Li S, Rong M and Iacopetta B: DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237: 272-280, 2006.
29. Parrella P, Poeta ML, Gallo AP, et al: Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10: 5349-5354, 2004.
30. Swift-Scanlan T, Vang R, Blackford A, Fackler MJ and Sukumar S: Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 11: 853-865, 2011.
31. Fackler MJ, McVeigh M, Evron E, et al: DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107: 970-975, 2003.
32. Yan L, Yang X and Davidson NE: Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 6: 183-192, 2001.
33. Lehmann U, Hasemeier B, Romermann D, Muller M, Langer F and Kreipe H: Epigenetic inactivation of microRNA genes in mammary carcinoma. Verh Dtsch Ges Pathol 91: 214-220, 2007 (In German).
34. Kapoor-Vazirani P, Kagey JD, Powell DR and Vertino PM: Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68: 6810-6821, 2008.
35. Yang X, Karuturi RK, Sun F, et al: CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4: e5011, 2009.
36. Chen J, Luo Q, Yuan Y, et al: Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol Cell Biol 30: 5621-5635, 2010.
37. Shi L, Sun L, Li Q, et al: Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 108: 7541-7546, 2011.
38. Wang Y, Zhang H, Chen Y, et al: LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660-672, 2009.
39. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al: mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17: 3600-3618, 2011.
40. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
41. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
42. Walter BA, Gomez-Macias G, Valera VA, Sobel M and Merino MJ: miR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J Cancer 2: 67-75, 2011.
43. Hossain A, Kuo MT and Saunders GF: Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26: 8191-8201, 2006.
44. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008.
45. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T and Zhu Y: Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer. Cancer Lett 302: 47-53, 2011.
46. Bedford MT and van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47: 5274-5276, 1987.
47. Pakneshan P, Szyf M and Rabbani SA: Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 5: 471-488, 2005.
48. Cho B, Lee H, Jeong S, et al: Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 307: 52-63, 2003.
49. Tokizane T, Shiina H, Igawa M, et al: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 11: 5793-5801, 2005.
50. Laner T, Schulz WA, Engers R, Muller M and Florl AR: Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res 15: 257-264, 2005.
51. Reibenwein J, Pils D, Horak P, et al: Promoter hypermethylation of GSTP1, AR, and 14-3-3σ in serum of prostate cancer patients and its clinical relevance. Prostate 67: 427-432, 2007.
52. Dammann R, Schagdarsurengin U, Liu L, et al: Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22: 3806-3812, 2003.
53. Woodson K, Hayes R, Wideroff L, Villaruz L and Tangrea J: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 55: 199-205, 2003.
54. Phe V, Cussenot O and Roupret M: Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int 104: 896-901, 2009.
55. Pulukuri SM, Patibandla S, Patel J, Estes N and Rao JS: Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229-5237, 2007.
56. Henrique R, Costa VL, Cerveira N, et al: Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 84: 911-918, 2006.
57. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M and Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266, 2005.
58. Ellinger J, Kahl P, von der Gathen J, et al: Global levels of histone modifications predict prostate cancer recurrence. Prostate 70: 61-69, 2010.
59. Muller I, Wischnewski F, Pantel K and Schwarzenbach H: Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications. BMC Cancer 10: 297, 2010.
60. Yu J, Cao Q, Mehra R, et al: Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12: 419-431, 2007.
61. Sikand K, Slaibi JE, Singh R, Slane SD and Shukla GC: miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer 129: 810-819, 2011.
62. Majid S, Dar AA, Saini S, et al: MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116: 5637-5649, 2010.
63. Mercatelli N, Coppola V, Bonci D, et al: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029, 2008.
64. Dong Q, Meng P, Wang T, et al: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5: e10147, 2010.
65. Peng X, Guo W, Liu T, et al: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6: e20341, 2011.
66. Fujita Y, Kojima K, Hamada N, et al: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119, 2008.
67. Lodygin D, Tarasov V, Epanchintsev A, et al: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600, 2008.
68. Lin SL, Chiang A, Chang D and Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424, 2008.
69. Rauch TA, Zhong X, Wu X, et al: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 105: 252-257, 2008.
70. Glazer CA, Smith IM, Ochs MF, et al: Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One 4: e8189, 2009.
71. Otterson GA, Khleif SN, Chen W, Coxon AB and Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11: 1211-1216, 1995.
72. Paz MF, Avila S, Fraga MF, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 62: 4519-4524, 2002.
73. Pereira MA, Tao L, Liu Y, Li L, Steele VE and Lubet RA: Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int J Cancer 120: 1150-1153, 2007.
74. Katayama H, Hiraki A, Fujiwara K, et al: Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Asian Pac J Cancer Prev 8: 221-224, 2007.
75. Licchesi JD, Westra WH, Hooker CM and Herman JG: Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14: 2570-2578, 2008.
76. Barski A, Cuddapah S, Cui K, et al: High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837, 2007.
77. Seligson DB, Horvath S, McBrian MA, et al: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174: 1619-1628, 2009.
78. Feng Y, Wang X, Xu L, et al: The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. FEBS J 276: 4197-4206, 2009.
79. Nonaka D, Fabbri A, Roz L, et al: Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer Res 65: 1207-1212, 2005.
80. Nishioka M, Kohno T, Tani M, et al: MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci USA 99: 12269-12274, 2002.
81. Chen MW, Hua KT, Kao HJ, et al: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 70: 7830-7840, 2010.
82. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
83. Grosshans H, Johnson T, Reinert KL, Gerstein M and Slack FJ: The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell 8: 321-330, 2005.
84. Lujambio A and Esteller M: CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6: 1455-1459, 2007.
85. Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. Cell 133: 217-222, 2008.
86. Saito M, Schetter AJ, Mollerup S, et al: The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 17: 1875-1882, 2011.
87. Fang JY, Lu R, Mikovits JA, Cheng ZH, Zhu HY and Chen YX: Regulation of h MSH2 and h MLH1 expression in the human colon cancer cell line SW1116 by DNA methyltransferase 1. Cancer Lett 233: 124-130, 2006.
88. Goel A, Arnold CN, Niedzwiecki D, et al: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64: 3014-3021, 2004.
89. Yuan BZ, Durkin ME and Popescu NC: Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 140: 113-117, 2003.
90. Thangaraju M, Carswell KN, Prasad PD and Ganapathy V: Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417: 379-389, 2009.
91. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137-147, 2008.
92. Godman CA, Joshi R, Tierney BR, et al: HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther 7: 1570-1580, 2008.
93. Tuttle R, Simon M, Hitch DC, et al: Senescence-associated gene YPEL3 is downregulated in human colon tumors. Ann Surg Oncol 18: 1791-1796, 2011.
94. Li Q and Chen H: Transcriptional silencing of N-Myc downstream-regulated gene 1 (NDRG1) in metastatic colon cancer cell line SW620. Clin Exp Metastasis 28: 127-135, 2011.
95. Menigatti M, Cattaneo E, Sabates-Bellver J, et al: The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer 8: 124, 2009.
96. Yadav S, Singhal J, Singhal SS and Awasthi S: hSET1: a novel approach for colon cancer therapy. Biochem Pharmacol 77: 1635-1641, 2009.
97. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S and Giaccia AJ: Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1α enhances hypoxic gene expression and tumor growth. Mol Cell Biol 30: 344-353, 2010.
98. Vlaicu SI, Tegla CA, Cudrici CD, et al: Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 88: 67-76, 2010.
99. Yin Q, Wang X, Fewell C, et al: MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol 84: 6318-6327, 2010.
100. Liu C, Kelnar K, Liu B, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215, 2011.
101. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590, 2007.
102. Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285, 2009.
103. Tang JT, Wang JL, Du W, et al: MicroRNA-345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 32: 1207-1215, 2011.
104. Schneider AC, Heukamp LC, Rogenhofer S, et al: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 1082: E290-E296, 2011.
105. Elsheikh SE, Green AR, Rakha EA, et al: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69: 3802-3809, 2009.
106. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al: Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14: 7237-7245, 2008.
107. Ellinger J, Kahl P, Mertens C, et al: Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 127: 2360-2366, 2010.
108. Ke XS, Qu Y, Rostad K, et al: Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 4: e4687, 2009.
109. Li Q, Wang X, Lu Z, et al: Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PLoS One 5: e13732, 2010.
110. McGarvey KM, Van Neste L, Cope L, et al: Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 68: 5753-5759, 2008.
111. Wei Y, Xia W, Zhang Z, et al: Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47: 701-706, 2008.
112. Pogribny IP, Tryndyak VP, Muskhelishvili L, Rusyn I and Ross SA: Methyl deficiency, alterations in global histone modifications, and carcinogenesis. J Nutr 137: 216S-222S, 2007.
113. Canaani E, Nakamura T, Rozovskaia T, Smith ST, Mori T, Croce CM and Mazo A: ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia. Br J Cancer 90: 756-760, 2004.
114. Liu H, Takeda S, Kumar R, et al: Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467: 343-346, 2010.
115. Scacheri PC, Davis S, Odom DT, et al: Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2: e51, 2006.
116. Seigne C, Fontaniere S, Carreira C, et al: Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer 10: 395, 2010.
117. Feng ZJ, Gao SB, Wu Y, Xu XF, Hua X and Jin GH: Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin. Oncogene 29: 5416-5426, 2010.
118. Wang J, Zhou Y, Yin B, et al: ASH2L: alternative splicing and downregulation during induced megakaryocytic differentiation of multipotential leukemia cell lines. J Mol Med 79: 399-405, 2001.
119. Magerl C, Ellinger J, Braunschweig T, et al: H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol 41: 181-189, 2010.
120. Kobayashi Y, Absher DM, Gulzar ZG, et al: DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21: 1017-1027, 2011.
121. Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618, 2011.
122. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM and Elemento O: EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116: 5247-5255, 2010.
123. Tell R, Rivera CA, Eskra J, Taglia LN, Blunier A, Wang QT and Benya RV: Gastrin-releasing peptide signaling alters colon cancer invasiveness via heterochromatin protein 1Hsß. Am J Pathol 178: 672-678, 2011.
124. Xi Y, Formentini A, Nakajima G, Kornmann M and Ju J: Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 19: 257-262, 2008.
125. Wang XQ, Miao X, Cai Q, Garcia-Barcelo MM and Fan ST: SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population. Exp Oncol 29: 71-73, 2007.
126. Oue N, Mitani Y, Motoshita J, et al: Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 106: 1250-1259, 2006.
127. Fang W, Piao Z, Buyse IM, Simon D, Sheu JC, Perucho M and Huang S: Preferential loss of a polymorphic RIZ allele in human hepatocellular carcinoma. Br J Cancer 84: 743-747, 2001.
128. Zhao Q, Caballero OL, Levy S, et al: Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci USA 106: 1886-1891, 2009.
129. Lucio-Eterovic AK, Singh MM, Gardner JE, Veerappan CS, Rice JC and Carpenter PB: Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc Natl Acad Sci USA 107: 16952-16957, 2010.
130. Berdasco M, Ropero S, Setien F, et al: Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 106: 21830-21835, 2009.
131. Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ and Kaneda Y: A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460: 287-291, 2009.
132. Taketani T, Taki T, Nakamura H, Taniwaki M, Masuda J and Hayashi Y: NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 190: 108-112, 2009.
133. Morishita M and di Luccio E: Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 1816: 158-163, 2011.
134. Watanabe H, Soejima K, Yasuda H, et al: Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 8: 15, 2008.
135. Visakorpi T, Suikki HE, Kujala PM, Tammela TLJ, van Weerden WM and Vessella RL: Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate 70: 889-898, 2010.
136. Fukuda T, Tokunaga A, Sakamoto R and Yoshida N: Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. Mol Cell Neurosci 46: 614-624, 2011.
137. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A and Streubel B: Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 14: 6426-6431, 2008.
138. Yang ZQ, Imoto I, Fukuda Y, et al: Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 60: 4735-4739, 2000.
139. Zeng J, Ge Z, Wang L, et al: The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 138: 981-992, 2010.
140. Rao M, Chinnasamy N, Hong JA, et al: Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 71: 4192-4204, 2011.
141. Liggins AP, Lim SH, Soilleux EJ, Pulford K and Banham AH: A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun 10: 8, 2010.
142. Jankowska A, Makishima H, Tiu RV, et al: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 116: 268-269, 2010.
143. Xiang Y, Zhu Z, Han G, Lin H, Xu L and Chen CD: JMJD3 is a histone H3K27 demethylase. Cell Res 17: 850-857, 2007.